CVS Caremark chief medical officer: Retail clinic model has ‘come of age’
WOONSOCKET, R.I. As CVS Caremark’s MinuteClinic passes the milestone of its first decade of delivering convenient access to quality care, and with the nation facing a historic expansion of the market for primary health care, MinuteClinic locations are poised to help primary care physicians handle the influx of 32 million citizens who will gain access to health insurance beginning in 2014, said Troyen Brennan, CVS Caremark chief medical officer, speaking at a Health Affairs Reinventing Primary Care conference on Tuesday in Washington, D.C.
During his presentation, Brennan outlined how the walk-in retail clinic model has "come of age" just as the need for new access points for basic health care is becoming more acute because of the growing shortage of primary care physicians, and with an influx of new patients needing care.
The good news, Brennan said, is that MinuteClinic receives better than 90% customer satisfaction rates while achieving good outcomes for their patients. In addition, the clinic is experiencing growing acceptance by commercial insurers and doctors, who at one time viewed the business with skepticism but have come to view clinics as complementary to their practices, CVS Caremark stated.
For example, MinuteClinic last week signed an agreement with Catholic Healthcare West, the eighth-largest hospital provider in the nation, to collaborate on healthcare services in communities throughout the Phoenix metropolitan area. MinuteClinic also has forged collaborations with Allina Hospitals & Clinics in Minnesota and the Cleveland Clinic. Brennan said the company expects to be announcing several additional relationships in the months ahead.
MinuteClinic was launched in 2000 and has served more than seven million patients over the past decade. The company has seen six million of those patients since 2007, reflecting steady growth that is based on:
- Providing convenient walk-in access to care by locating in CVS/pharmacy stores and offering extended night and weekend hours
- Providing quality care at relatively low costs. A study published in the Annals of Internal Medicine in September 2009 found that services for the similar illnesses by MinuteClinic were, on average, significantly less costly than services provided in a doctor’s office or emergency room service. The same study found the quality of MinuteClinic service was on a par with those provided in a doctor’s office and emergency room
- Sixty percent of MinuteClinic patients do not have a primary care physician. MinuteClinic plays an important role for these patients as a convenient source of care, and also refers patients to local physicians to develop medical home relationships.
In addition, MinuteClinic was the first retail healthcare provider to be accredited by the Joint Commission and in 2009 was re-accredited. MinuteClinic staff adheres to national standards of practice as established by the American Academy of Pediatrics, the American Academy of Family Physicians and the Institute for Clinical Systems.
"As health reform is implemented by Health and Human Services, we believe retail clinics offer complementary care that can help better manage medical costs," said Brennan. "MinuteClinic is a market innovation that should be considered as part of the solution to providing care to all our citizens."
NACDS names Guckian state affairs chief
ALEXANDRIA, Va. The National Association of Chain Drug Stores has named Sandra Kay Guckian, a pharmacy and policy veteran of the organization, as VP state government affairs.
Guckian, nee Sandra Jung, will oversee the work of five state government affairs directors based in regions throughout the U.S., as well as an administrative assistant based at NACDS headquarters. She reports directly to Carol Kelly, NACDS’ SVP government affairs and public policy.
In addition to leading the state government affairs team, Guckian manages state-level legislative and regulatory advocacy in Delaware, Maryland, Pennsylvania, Virginia and the District of Columbia.
Guckian replaces Gary Wirth, who has left the association to pursue other interests, according to NACDS spokesperson Chrissy Kopple. The appointment is effective immediately.
Guckian is one of the longest-serving members of NACDS’ management team, and last served as VP and deputy director of state government affairs. NACDS president and CEO Steve Anderson called her promotion “the latest step in the transformation of NACDS to maximize its strategic focus and effectiveness.
“In her 13 years at NACDS, Sandra has established a reputation as a member-focused, highly substantive and strategically oriented leader who is absolutely passionate about pharmacy,” said Anderson. “Sandra is well equipped to work collaboratively with NACDS member company representatives, with state association partners, and with her dedicated colleagues on the state government affairs team and throughout NACDS to help advance pharmacy at all levels of government for the ultimate benefit of patient care.”
Guckian earned her B.S. in Pharmacy and M.S. in Pharmacy from The University of Texas at Austin College of Pharmacy, and completed an accredited residency at Parkland Memorial Hospital. She has practiced as a pharmacist in a variety of settings including community retail pharmacy, hospital pharmacy and home health care practice.
FDA: Certain prostate cancer drugs may cause other health problems
SILVER SPRING, Md. The Food and Drug Administration is investigating a possible link between drugs commonly used to treat prostate cancer and a risk of serious health problems, the agency said Monday.
The FDA said it was conducting a safety review of gonadotropin-releasing hormone agonists, saying they have been associated with a “small increased risk” for diabetes, heart attack, stroke and sudden death. The agency is suggesting that healthcare professionals monitor men using the drugs, but that patients should not stop using them unless directed to do so. It also cautioned that it had not made any conclusions about whether the drugs cause an increase in the risk of developing heart disease and diabetes.
GnRH agonists include such branded drugs as Abbott’s Lupron (leuprolide acetate), Watson’s Trelstar (triptorelin pamoate) and several generic drugs.